ALFA Filings
Every announcement, straight from the exchange
Every Jagsonpal Pharmaceuticals earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
5 announcements
Q2FY27 consolidated revenue ₹964 Mn (+29%, Aequitas consolidated); standalone revenue ₹814 Mn (+9.3%), EBITDA margin 22.7%, PAT ₹126 Mn flat. H1 standalone PAT +10.3%.
Jagsonpal reported a strong Q1FY27 with 9% revenue growth and 22% PAT growth, outperforming industry rates. The focus is on higher-margin specialty segments and integrating the Equitas acquisition to enter the hospital channel.
Jagsonpal Pharmaceuticals reported a strong start to FY27 with revenue up 9% YoY and PAT up 22%. The company completed the Aequitas acquisition to enter the hospital supplies segment.
Jagsonpal reported Q4 revenue of ₹64cr (up 10% YoY) and FY26 revenue of ₹287cr (up 7%). Strategy focuses on MR productivity and portfolio rejuvenation in Gynaecology and Dermatology.
Jagsonpal Pharmaceuticals reported strong FY26 results with 7% revenue growth and 19% PAT growth. Strategy focuses on an asset-light model, high-margin Rx brands, and shareholder returns via buybacks and dividends.